Loading content
Prof Alison Curnow

Prof Alison Curnow

Associate Professor in Science & Scholarship

01872 256432

Knowledge Spa S10

Alison is a senior member of the University of Exeter Medical School’s academic teaching faculty and the majority of her working week is dedicated to developing and delivering the School’s medical and scientific undergraduate and postgraduate programmes. She is currently Deputy Director of Undergraduate Medicine (BMBS) as well as the Programme Lead for our MSc in Environment & Human Health.

With over two decades’ experience of conducting translational photobiological and oncological related research, she is known worldwide for her photodynamic therapy (PDT) research and leadership (Secretary General (2009-13) and Director (2005-16) of the International Photodynamic Association and  Editor of the Journal of Photochemistry & Photobiology B: Biology (2001-10)).

Broad research specialisms

She leads the Clinical Photobiology research team, which forms part of the European Centre for Environment & Human Health (ECEHH). The primary focus of their experimental and clinical research programmes is the causation, prevention and treatment of skin cancer. Non-melanoma skin cancer (NMSC) is the most common type of cancer in Western Europe. She has established (with clinical colleagues at Royal Cornwall Hospital), one of the top dermatological photodynamic therapy (PDT) groups in Europe, running an active standard PDT treatment service and a parallel clinical research programme with a view to improving the effectiveness and diversifying the application of this non-invasive light-mediated treatment of skin cancer and precancer.

Qualifications

Alison is an experienced educator with a wide range of high quality teaching, assessment and curriculum development skills. As a result she has been made a Fellow of the Higher Education Academy (FHEA) building on the educational scholarship she developed whilst undertaking her Postgraduate Certificate in Education (PGCE).  She is an active ASPIRE participant and mentor and has completed the Leadership Foundation's Aurora, Developing Women Leaders in Higher Education programme.

She has a PhD in Surgery from University College London and a BSc (Hons) in Medical Biochemistry from the University of Surrey.

Career

Alison's research career began as a Research Assistant for the Imperial Cancer Research Fund, conducting clinical studies to investigate chemotherapy agents for terminally ill breast cancer patients at Guy’s Hospital London.  Her interest in photobiology was established at the National Medical Laser Centre, University College London where she completed her PhD part-time whilst working as a Research Fellow to investigate a light-activated, cancer drug therapy (photodynamic therapy).  This led to a post-doctoral position to manage and extend the skin cancer research portfolio at Royal Cornwall Hospital, Truro for the Cornwall Dermatology Research Project and appointment as the first female and youngest Editor of the Journal of Photochemistry & Photobiology B: Biology.  This research portfolio evolved to become part of the Peninsula Medical School in 2003 and more recently the University of Exeter Medical School with Alison's academic appointments first as Lecturer and then Senior Lecturer in Cell and Molecular Biology, followed by Senior Lecturer and now Associate Professor in Science and Scholarship.  Alison is also a Director of the International Photodynamic Association (2005 to present) and the society's former Secretary General (2009-13).

Research

Research interests

Alison has established a highly respected dermatological photodynamic therapy (PDT) group, embedded within the photodynamic therapy treatment service at Royal Cornwall Hospital, Truro.  This clinical research programme has improved the effectiveness of this non-invasive light-mediated treatment of skin cancer and precancer (the most common type of cancer in the Western World) and has therefore had a significant impact on patient care.  

Experimental research projects (conducted mainly with human skin cells at the Environment and Sustainability Institute on the Penryn Campus) include investigations of the mechanism and enhancement of PDT, the use of natural products to prevent the DNA damage caused by sunlight and determining the biological effects that compounds may have with or without the presence of ultraviolet radiation (including environmental contaminants such as arsenic, radon, polyaromatic hydrocarbons and airborne particulate matter).

This photobiological research programme focuses on oxidative stress as both PDT and ultraviolet radiation can produce reactive oxygen species.

Key publications | Publications by category | Publications by year

Key publications


Tyrrell JS, Morton C, Campbell SM, Curnow A (2011). Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. Br J Dermatol, 164(6), 1362-1368. Abstract.  Author URL.  Full text.
Tyrrell J, Thorn C, Shore A, Campbell S, Curnow A (2011). Oxygen saturation and perfusion changes during dermatological methyl-aminolevulinate photodynamic therapy. British Journal of Dermatology Full text.
Tyrrell JS, Campbell SM, Curnow A (2010). The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Lasers Surg Med, 42(7), 613-619. Abstract.  Author URL.  Full text.
Campbell SM, Morton CA, Alyahya R, Horton S, Pye A, Curnow A (2008). Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol, 159(2), 387-393. Abstract.  Author URL.  Full text.

Publications by category


Journal articles

Curnow A, Horton SJ (In Press). An evaluation of root phytochemicals derived from Althea officinalis (Marshmallow) and Astragalus membranaceus as potential natural components of UV-protecting dermatological formulations. Oxidative Medicine and Cellular Longevity Abstract.  Full text.
Dogra Y, Ferguson DCJ, Dodd NJF, Smerdon GR, Curnow A, Winyard PG (2016). The hydroxypyridinone iron chelator CP94 increases methyl-aminolevulinate-based photodynamic cell killing by increasing the generation of reactive oxygen species. Redox Biol, 9, 90-99. Abstract.  Author URL.  Full text.
Curnow A, MacRobert AJ, Bown SG (2015). Enhancing Protoporphyrin IX-induced Photodynamic Therapy with a Topical Iron Chelating Agent in a Normal Skin Model. Journal of Heavy Metal Toxicity and Diseases, 1(1), 1-9. Abstract.  Full text.
Curnow A, Pye A (2015). The importance of iron chelation and iron availability during PpIX-induced photodynamic therapy. Photonics and Lasers in Medicine, 4(1), 39-58. Full text.
Blake E, Allen J, Thorn C, Shore A, Curnow A (2013). Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy. Lasers in Medical Science, 28(3), 997-1005. Abstract.  Full text.
Robertson A, Allen J, Laney R, Curnow A (2013). The cellular and molecular carcinogenic effects of radon exposure: a review. Int J Mol Sci, 14(7), 14024-14063. Abstract.  Author URL.  Full text.
Blake E, Allen J, Curnow A (2013). The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions. Photodiagnosis and Photodynamic Therapy, 10(4), 575-582. Abstract.
Ferguson D, Smerdon GR, Eggleton P, Curnow A, Winyard PG (2012). Altering oxygen concentrations to enhance the efficacy of PpIX-based photodynamic cell killing. FREE RADICAL BIOLOGY AND MEDICINE, 53, S127-S127. Author URL.
Wheeler BW, Allen J, Depledge MH, Curnow A (2012). Radon and skin cancer in southwest England: an ecologic study. Epidemiology, 23(1), 44-52. Abstract.  Full text.
Blake E, Campbell S, Allen J, Mathew J, Helliwell P, Curnow A (2012). The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device. J Photochem Photobiol B, 117, 97-103. Abstract.  Author URL.  Full text.
Blake E, Allen J, Curnow A (2011). An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection. Photochem Photobiol, 87(6), 1419-1426. Abstract.  Author URL.  Full text.
Morris J, Laing-Morton T, Marno P, Curnow A (2011). An investigation into the awareness and understanding of the ultraviolet index forecasts in the South West of England. Photochem. Photobiol. Sci. Abstract.
Tyrrell JS, Morton C, Campbell SM, Curnow A (2011). Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. Br J Dermatol, 164(6), 1362-1368. Abstract.  Author URL.  Full text.
Tyrrell J, Campbell SM, Curnow A (2011). Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification. Photodiagnosis Photodyn Ther, 8(1), 30-38. Abstract.  Author URL.  Full text.
Tyrrell J, Thorn C, Shore A, Campbell S, Curnow A (2011). Oxygen saturation and perfusion changes during dermatological methyl-aminolevulinate photodynamic therapy. British Journal of Dermatology Full text.
Tyrrell J, Campbell SM, Curnow A (2011). The effect of air cooling pain relief on protoporphyrin IX photobleaching and clinical efficacy during dermatological photodynamic therapy. J Photochem Photobiol B, 103(1), 1-7. Abstract.  Author URL.
Curnow A, Campbell SM (2010). Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification. Br J Dermatol, 162(1), 224-225. Author URL.
Campbell SM, Tyrrell J, Marshall R, Curnow A (2010). Effect of MAL-photodynamic therapy on hypertrophic scarring. Photodiagnosis Photodyn Ther, 7(3), 183-188. Abstract.  Author URL.
Tyrrell J, Campbell S, Curnow A (2010). Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy. Photodiagnosis Photodyn Ther, 7(4), 232-238. Abstract.  Author URL.
Blake E, Curnow A (2010). The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. Photochem Photobiol, 86(5), 1154-1160. Abstract.  Author URL.
Tyrrell JS, Campbell SM, Curnow A (2010). The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Lasers Surg Med, 42(7), 613-619. Abstract.  Author URL.  Full text.
Malhomme de la Roche H, Seagrove S, Mehta A, Divekar P, Campbell S, Curnow A (2010). Using natural dietary sources of antioxidants to protect against ultraviolet and visible radiation-induced DNA damage: an investigation of human green tea ingestion. J Photochem Photobiol B, 101(2), 169-173. Abstract.  Author URL.
Tyrrell J, Campbell S, Curnow A (2010). Validation of a non-invasive fluorescence imaging system to monitor dermatological PDT. Photodiagnosis Photodyn Ther, 7(2), 86-97. Abstract.  Author URL.  Full text.
Curnow A (2009). 12th World Congress of the International Photodynamic Association (IPA), 11-15th June 2009, Seattle, USA. Photodiagnosis Photodyn Ther, 6(2), 150-151. Author URL.
Curnow A, Dogra Y, Winyard PG, Campbell S (2009). Using iron chelating agents to enhance dermatological PDT.
Campbell SM, Morton CA, Alyahya R, Horton S, Pye A, Curnow A (2008). Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol, 159(2), 387-393. Abstract.  Author URL.  Full text.
Donnelly RF, Curnow A, Demir YK, Singh RRT, McCarron PA, Woolfson AD (2008). Co-delivery of 5-aminolevulinic acid and the novel hydroxypyridinone iron chelator CP-94 from bioadhesive patches for enhanced topical photodynamic therapy. JOURNAL OF PHARMACY AND PHARMACOLOGY, 60, A21-A22. Author URL.
Pye A, Campbell S, Curnow A (2008). Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. J Cancer Res Clin Oncol, 134(8), 841-849. Abstract.  Author URL.  Full text.
Campbell SM, Curnow A (2008). Extensive vulval intraepithelial neoplasia treated with a new regime of systemic photodynamic therapy using meta-tetrahydroxychlorin (Foscan). J Eur Acad Dermatol Venereol, 22(4), 502-503. Author URL.
Campbell SM, Pye A, Horton S, Matthew J, Helliwell P, Curnow A (2007). A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin. J Environ Pathol Toxicol Oncol, 26(4), 295-303. Abstract.  Author URL.
ACurnow, Pye A (2007). Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. Photochemistry and Photobiology, 83(3), 766-773.
Curnow A, MacRobert AJ, Bown SG (2006). Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med, 38(4), 325-331. Abstract.  Author URL.
Bradfield W, Pye A, Clifford T, Salter L, Gould D, Campbell S, Curnow A (2006). Hg(II) exposure exacerbates UV-induced DNA damage in MRC5 fibroblasts: a comet assay study. J Environ Sci Health a Tox Hazard Subst Environ Eng, 41(2), 143-148. Abstract.  Author URL.
Morley N, Rapp A, Dittmar H, Salter L, Gould D, Greulich KO, Curnow A (2006). UVA-induced apoptosis studied by the new apo/necro-Comet-assay which distinguishes viable, apoptotic and necrotic cells. Mutagenesis, 21(2), 105-114. Abstract.  Author URL.
Morley N, Clifford T, Salter L, Campbell S, Gould D, Curnow A (2005). The green tea polyphenol (-)-epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage. Photodermatol Photoimmunol Photomed, 21(1), 15-22. Abstract.  Author URL.
Campbell SM, Gould DJ, Salter L, Clifford T, Curnow A (2004). Photodynamic therapy using meta-tetrahydroxyphenylchlorin (Foscan) for the treatment of vulval intraepithelial neoplasia. Br J Dermatol, 151(5), 1076-1080. Abstract.  Author URL.
Salter L, Clifford T, Morley N, Gould D, Campbell S, Curnow A (2004). The use of comet assay data with a simple reaction mechanism to evaluate the relative effectiveness of free radical scavenging by quercetin, epigallocatechin gallate and N-acetylcysteine in UV-irradiated MRC5 lung fibroblasts. J Photochem Photobiol B, 75(1-2), 57-61. Abstract.  Author URL.
Morley N, Curnow A, Salter L, Campbell S, Gould D (2003). N-acetyl-L-cysteine prevents DNA damage induced by UVA, UVB and visible radiation in human fibroblasts. J Photochem Photobiol B, 72(1-3), 55-60. Abstract.  Author URL.
Kömerik N, Curnow A, MacRobert AJ, Hopper C, Speight PM, Wilson M (2002). Fluorescence biodistribution and photosensitising activity of toluidine blue o on rat buccal mucosa. Lasers Med Sci, 17(2), 86-92. Abstract.  Author URL.
Tsutsui H, MacRobert AJ, Curnow A, Rogowska A, Buonaccorsi G, Kato H, Bown SG (2002). Optimisation of illumination for photodynamic therapy with mTHPC on normal colon and a transplantable tumour in rats. Lasers Med Sci, 17(2), 101-109. Abstract.  Author URL.
Curnow A, Salter L, Morley N, Campbell S, Gould D (2002). Paracetamol can exacerbate irradiation-induced DNA damage. Br J Clin Pharmacol, 53(3), 338-340. Author URL.
Curnow A, Bown SG (2002). The role of reperfusion injury in photodynamic therapy with 5-aminolaevulinic acid--a study on normal rat colon. Br J Cancer, 86(6), 989-992. Abstract.  Author URL.  Full text.
ACurnow, Bown S (2002). The role of reperfusion injury in photodynamic therapy with aminolaevulinic acid - a study on normal rat colon. British Journal of Cancer, 86(6), 989-992.
Curnow A, Salter L, Morley N, Gould D (2001). A preliminary investigation of the effects of arsenate on irradiation-induced DNA damage in cultured human lung fibroblasts. J Toxicol Environ Health A, 63(8), 605-616. Abstract.  Author URL.
Connell RJ, Curnow A, Cutner A, Brown S (2000). Endometrial ablation in the rabbit uterus by photodynamic therapy (PDT) using 5-aminolaevulinic acid with the iron chelator CP94. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 107(6), 828-828. Author URL.
Curnow A, Haller JC, Bown SG (2000). Oxygen monitoring during 5-aminolaevulinic acid induced photodynamic therapy in normal rat colon. Comparison of continuous and fractionated light regimes. J Photochem Photobiol B, 58(2-3), 149-155. Abstract.  Author URL.  Full text.
Curnow A, McIlroy BW, Postle-Hacon MJ, MacRobert AJ, Bown SG (1999). Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol, 69(1), 71-76. Abstract.  Author URL.
Curnow A, McIlroy B, Postle-Hacon M, Porter J, MacRobert A, Bown S (1998). Enhancement of 5-aminolaevulinic acid induced photodynamic therapy using iron chelating agents. British Journal of Cancer, 78, 1278-1282.
Curnow A, McIlroy BW, Postle-Hacon MJ, Porter JB, MacRobert AJ, Bown SG (1998). Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Br J Cancer, 78(10), 1278-1282. Abstract.  Author URL.  Full text.
McIlroy BW, Curnow A, Buonaccorsi G, Scott MA, Bown SG, MacRobert AJ (1998). Spatial measurement of oxygen levels during photodynamic therapy using time-resolved optical spectroscopy. J Photochem Photobiol B, 43(1), 47-55. Abstract.  Author URL.
Komerik N, Speight P, Curnow A, Postle-Hacon M, Wilson M, Hopper C (1998). The effect of photodynamic therapy on rat buccal mucosa. JOURNAL OF DENTAL RESEARCH, 77, 754-754. Author URL.
Twelves CJ, Dobbs NA, Curnow A, Coleman RE, Stewart AL, Tyrrell CJ, Canney P, Rubens RD (1994). A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer, 70(5), 990-993. Abstract.  Author URL.  Full text.

Chapters

Curnow A, Tyrrell J (2015). The mechanism of action of topical dermatological photodynamic therapy. In  (Ed) Photodynamic Therapy: Fundamentals, Applications and Health Outcomes, 59-102.
Pye A, Dogra Y, Tyrrell J, Winyard P, Curnow A (2009). Photodynamic therapy with aminolaevulinic acid and iron chelators: a clinical example of redox signaling. In Jacob C, Winyard P (Eds.) Redox signaling and regulation in biology and medicine, Weinheim: Wiley-VCH, 381-404.
Pye A, Dogra Y, Tyrrell J, Winyard PG, Curnow A (2009). Photodynamic therapy with aminolevulinic acid and iron chelators: a clinical example of redox signaling. In Jacob C, Winyard PG, Wiley-VCH (Eds.) Redox Signaling and Regulation in Biology and Medicine, Weinheim, Germany: , 351-372.
Curnow A (2006). Potential Future Indications. In Pottier R, Krammer B, Stepp H, Baumgartner R (Eds.) Photodynamic therapy with ALA: a clinical handbook, Cambridge: Royal Society of Chemistry, 249-259.

Conferences

Wilkinson C, Saunders M, Curnow A (2010). Measures of ultraviolet radiation in the South West.  Author URL.
Curnow A, Pye A, Campbell S (2009). Enhancing protoporphyrin IX-induced PDT. Photodynamic Therapy - Back to the Future.  Abstract.
Tyrrell J, Campbell S, Curnow A (2009). The utilization of a non-invasive fluorescence imaging system to follow clinical dermatological MAL-PDT. Photodynamic Therapy - Back to the Future.  Abstract.
McGovern G, Tyrrell J, Campbell S, Curnow A (2008). Audit on the use of photodynamic therapy (PDT) for various malignant and pre-malignant skin conditions. British Association of Dermatology.
Tyrrell J, Shore A, Curnow A (2008). Monitoring clinical dermatological photodynamic therapy: validation of a noninvasive fluorescence imaging system.  Author URL.
Curnow A, Peng Q (2007). 11th World Congress of the International Photodynamic Association (IPA) – meeting report.
Campbell S, Horton S, Curnow A (2007). A pilot study to determine the effect of pressure injection on the penetration of topical methyl aminolaevulinic acid (MAL) into nodular basal cell carcinoma (nBCC) of the skin.  Author URL.
Curnow A, Pye A (2007). Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors.  Abstract.  Author URL.
Pye A, Curnow A (2007). DNA damage in photodynamic therapy through the production of reactive oxygen species parallels that of ionizing radiation and UVA.  Author URL.
Dogra Y, Curnow A, Winyard P (2007). Mechanisms of cell death induced by dermatological protoporphyrin IX-induced photodynamic therapy.  Author URL.
Pye A, Hallaq H, Horton S, Curnow A (2006). An in vitro investigation of 5-aminolaevulinic acid and methyl aminotaevulinate photodynamic therapy enhancement by iron removal using CP94.  Author URL.
Pye AJ, Wakeman TD, Horton SJ, Campbell SM, Salter L, Curnow A (2006). An in vitro investigation of the genotoxic role of iron during aminolaevulinic acid photodynamic therapy.  Author URL.
Adie K, Moody A, Pye A, Curnow A (2006). Does chronic therapeutic paracetamol use predispose to oxidative stress?.
Pye AJ, Campbell SM, Horton SJ, Salter L, Curnow A (2005). An in vitro investigation of the enhancement of 5-aminolaevulinic acid-induced photodynamic therapy for the treatment of nodular basal cell carcinoma using the hydroxypyridinone iron chelator CP94.  Author URL.
Curnow A, Campbell S, Leman J, Morton C, Salter L (2005). Enhancement of dermatological ALA-PDT with an iron chelating agent (CP94).
Campbell S, Gould D, Salter L, Curnow A (2005). Penile intraepidermal neoplasia treated with MAL-PDT.  Author URL.
Morley N, Clifford T, Salter L, Campbell S, Gould D, Pye A, Curnow A (2004). The green tea polyphenol (-)-epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage.  Author URL.
Morton CA, Campbell S, Gould D, Curnow A (2004). Topical photodynamic therapy with the iron chelator, CP94, for nodular basal cell carcinoma.  Author URL.
Campbell S, Leman J, Curnow A, Morton C, Salter L, Gould D (2003). Enhancing dermatological 5-aminolaevulinic acid-photodynamic therapy with a novel iron chelator.  Author URL.
Gould D, Curnow A, Morley N, Salter L (2003). Synergy between pollutants and ultraviolet radiation: a comet assay investigation.  Author URL.
Morley RN, Dittmar H, Curnow A, Salter L, Gould D, Greulich KO (2003). Two waves of apoptosis occur after UV-A exposure as detected with repeated scanning comet-assay.  Author URL.
Stentiford FWM, Morley N, Curnow A (2002). Automatic identification of regions of interest with application to the quantification of DNA damage in cells.  Author URL.
Curnow A, Parsons B, Salter L, Morley N, Gould D (2001). An investigation of the genotoxic effects of airborne particulate matter using single-cell gel electrophoresis.
Curnow A, Gould D, Salter L (2000). A new method for the cultivation of human naevus melanocytes.
Curnow A, Postle-Hacon MJ, MacRobert AJ, Brown SG (1998). Enhancement of 5-aminolaevulinic acid induced photodynamic therapy using light dose fractionation and iron chelating agents.  Author URL.

Publications by year


In Press

Curnow A, Horton SJ (In Press). An evaluation of root phytochemicals derived from Althea officinalis (Marshmallow) and Astragalus membranaceus as potential natural components of UV-protecting dermatological formulations. Oxidative Medicine and Cellular Longevity Abstract.  Full text.
Curnow A (In Press). Novel iron chelating prodrug (AP2-18) for protoporphyrin IX-induced photodynamic therapy.  Abstract.

2016

Dogra Y, Ferguson DCJ, Dodd NJF, Smerdon GR, Curnow A, Winyard PG (2016). The hydroxypyridinone iron chelator CP94 increases methyl-aminolevulinate-based photodynamic cell killing by increasing the generation of reactive oxygen species. Redox Biol, 9, 90-99. Abstract.  Author URL.  Full text.

2015

Curnow A, MacRobert AJ, Bown SG (2015). Enhancing Protoporphyrin IX-induced Photodynamic Therapy with a Topical Iron Chelating Agent in a Normal Skin Model. Journal of Heavy Metal Toxicity and Diseases, 1(1), 1-9. Abstract.  Full text.
Curnow A, Pye A (2015). The importance of iron chelation and iron availability during PpIX-induced photodynamic therapy. Photonics and Lasers in Medicine, 4(1), 39-58. Full text.
Curnow A, Tyrrell J (2015). The mechanism of action of topical dermatological photodynamic therapy. In  (Ed) Photodynamic Therapy: Fundamentals, Applications and Health Outcomes, 59-102.

2013

Blake E, Allen J, Thorn C, Shore A, Curnow A (2013). Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy. Lasers in Medical Science, 28(3), 997-1005. Abstract.  Full text.
Robertson A, Allen J, Laney R, Curnow A (2013). The cellular and molecular carcinogenic effects of radon exposure: a review. Int J Mol Sci, 14(7), 14024-14063. Abstract.  Author URL.  Full text.
Blake E, Allen J, Curnow A (2013). The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions. Photodiagnosis and Photodynamic Therapy, 10(4), 575-582. Abstract.

2012

Ferguson D, Smerdon GR, Eggleton P, Curnow A, Winyard PG (2012). Altering oxygen concentrations to enhance the efficacy of PpIX-based photodynamic cell killing. FREE RADICAL BIOLOGY AND MEDICINE, 53, S127-S127. Author URL.
Wheeler BW, Allen J, Depledge MH, Curnow A (2012). Radon and skin cancer in southwest England: an ecologic study. Epidemiology, 23(1), 44-52. Abstract.  Full text.
Blake E, Campbell S, Allen J, Mathew J, Helliwell P, Curnow A (2012). The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device. J Photochem Photobiol B, 117, 97-103. Abstract.  Author URL.  Full text.

2011

Blake E, Allen J, Curnow A (2011). An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection. Photochem Photobiol, 87(6), 1419-1426. Abstract.  Author URL.  Full text.
Morris J, Laing-Morton T, Marno P, Curnow A (2011). An investigation into the awareness and understanding of the ultraviolet index forecasts in the South West of England. Photochem. Photobiol. Sci. Abstract.
Tyrrell JS, Morton C, Campbell SM, Curnow A (2011). Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. Br J Dermatol, 164(6), 1362-1368. Abstract.  Author URL.  Full text.
Tyrrell J, Campbell SM, Curnow A (2011). Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification. Photodiagnosis Photodyn Ther, 8(1), 30-38. Abstract.  Author URL.  Full text.
Tyrrell J, Thorn C, Shore A, Campbell S, Curnow A (2011). Oxygen saturation and perfusion changes during dermatological methyl-aminolevulinate photodynamic therapy. British Journal of Dermatology Full text.
Tyrrell J, Campbell SM, Curnow A (2011). The effect of air cooling pain relief on protoporphyrin IX photobleaching and clinical efficacy during dermatological photodynamic therapy. J Photochem Photobiol B, 103(1), 1-7. Abstract.  Author URL.

2010

Curnow A, Campbell SM (2010). Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification. Br J Dermatol, 162(1), 224-225. Author URL.
Campbell SM, Tyrrell J, Marshall R, Curnow A (2010). Effect of MAL-photodynamic therapy on hypertrophic scarring. Photodiagnosis Photodyn Ther, 7(3), 183-188. Abstract.  Author URL.
Wilkinson C, Saunders M, Curnow A (2010). Measures of ultraviolet radiation in the South West.  Author URL.
Tyrrell J, Campbell S, Curnow A (2010). Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy. Photodiagnosis Photodyn Ther, 7(4), 232-238. Abstract.  Author URL.
Blake E, Curnow A (2010). The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. Photochem Photobiol, 86(5), 1154-1160. Abstract.  Author URL.
Tyrrell JS, Campbell SM, Curnow A (2010). The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Lasers Surg Med, 42(7), 613-619. Abstract.  Author URL.  Full text.
Malhomme de la Roche H, Seagrove S, Mehta A, Divekar P, Campbell S, Curnow A (2010). Using natural dietary sources of antioxidants to protect against ultraviolet and visible radiation-induced DNA damage: an investigation of human green tea ingestion. J Photochem Photobiol B, 101(2), 169-173. Abstract.  Author URL.
Tyrrell J, Campbell S, Curnow A (2010). Validation of a non-invasive fluorescence imaging system to monitor dermatological PDT. Photodiagnosis Photodyn Ther, 7(2), 86-97. Abstract.  Author URL.  Full text.

2009

Curnow A (2009). 12th World Congress of the International Photodynamic Association (IPA), 11-15th June 2009, Seattle, USA. Photodiagnosis Photodyn Ther, 6(2), 150-151. Author URL.
Curnow A, Pye A, Campbell S (2009). Enhancing protoporphyrin IX-induced PDT. Photodynamic Therapy - Back to the Future.  Abstract.
Pye A, Dogra Y, Tyrrell J, Winyard P, Curnow A (2009). Photodynamic therapy with aminolaevulinic acid and iron chelators: a clinical example of redox signaling. In Jacob C, Winyard P (Eds.) Redox signaling and regulation in biology and medicine, Weinheim: Wiley-VCH, 381-404.
Pye A, Dogra Y, Tyrrell J, Winyard PG, Curnow A (2009). Photodynamic therapy with aminolevulinic acid and iron chelators: a clinical example of redox signaling. In Jacob C, Winyard PG, Wiley-VCH (Eds.) Redox Signaling and Regulation in Biology and Medicine, Weinheim, Germany: , 351-372.
Tyrrell J, Campbell S, Curnow A (2009). The utilization of a non-invasive fluorescence imaging system to follow clinical dermatological MAL-PDT. Photodynamic Therapy - Back to the Future.  Abstract.
Curnow A, Dogra Y, Winyard PG, Campbell S (2009). Using iron chelating agents to enhance dermatological PDT.

2008

McGovern G, Tyrrell J, Campbell S, Curnow A (2008). Audit on the use of photodynamic therapy (PDT) for various malignant and pre-malignant skin conditions. British Association of Dermatology.
Campbell SM, Morton CA, Alyahya R, Horton S, Pye A, Curnow A (2008). Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol, 159(2), 387-393. Abstract.  Author URL.  Full text.
Donnelly RF, Curnow A, Demir YK, Singh RRT, McCarron PA, Woolfson AD (2008). Co-delivery of 5-aminolevulinic acid and the novel hydroxypyridinone iron chelator CP-94 from bioadhesive patches for enhanced topical photodynamic therapy. JOURNAL OF PHARMACY AND PHARMACOLOGY, 60, A21-A22. Author URL.
Pye A, Campbell S, Curnow A (2008). Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. J Cancer Res Clin Oncol, 134(8), 841-849. Abstract.  Author URL.  Full text.
Campbell SM, Curnow A (2008). Extensive vulval intraepithelial neoplasia treated with a new regime of systemic photodynamic therapy using meta-tetrahydroxychlorin (Foscan). J Eur Acad Dermatol Venereol, 22(4), 502-503. Author URL.
Tyrrell J, Shore A, Curnow A (2008). Monitoring clinical dermatological photodynamic therapy: validation of a noninvasive fluorescence imaging system.  Author URL.

2007

Curnow A, Peng Q (2007). 11th World Congress of the International Photodynamic Association (IPA) – meeting report.
Campbell SM, Pye A, Horton S, Matthew J, Helliwell P, Curnow A (2007). A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin. J Environ Pathol Toxicol Oncol, 26(4), 295-303. Abstract.  Author URL.
Campbell S, Horton S, Curnow A (2007). A pilot study to determine the effect of pressure injection on the penetration of topical methyl aminolaevulinic acid (MAL) into nodular basal cell carcinoma (nBCC) of the skin.  Author URL.
Curnow A, Pye A (2007). Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors.  Abstract.  Author URL.
Pye A, Curnow A (2007). DNA damage in photodynamic therapy through the production of reactive oxygen species parallels that of ionizing radiation and UVA.  Author URL.
ACurnow, Pye A (2007). Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. Photochemistry and Photobiology, 83(3), 766-773.
Dogra Y, Curnow A, Winyard P (2007). Mechanisms of cell death induced by dermatological protoporphyrin IX-induced photodynamic therapy.  Author URL.

2006

Pye A, Hallaq H, Horton S, Curnow A (2006). An in vitro investigation of 5-aminolaevulinic acid and methyl aminotaevulinate photodynamic therapy enhancement by iron removal using CP94.  Author URL.
Pye AJ, Wakeman TD, Horton SJ, Campbell SM, Salter L, Curnow A (2006). An in vitro investigation of the genotoxic role of iron during aminolaevulinic acid photodynamic therapy.  Author URL.
Curnow A, MacRobert AJ, Bown SG (2006). Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med, 38(4), 325-331. Abstract.  Author URL.
Adie K, Moody A, Pye A, Curnow A (2006). Does chronic therapeutic paracetamol use predispose to oxidative stress?.
Bradfield W, Pye A, Clifford T, Salter L, Gould D, Campbell S, Curnow A (2006). Hg(II) exposure exacerbates UV-induced DNA damage in MRC5 fibroblasts: a comet assay study. J Environ Sci Health a Tox Hazard Subst Environ Eng, 41(2), 143-148. Abstract.  Author URL.
Curnow A (2006). Potential Future Indications. In Pottier R, Krammer B, Stepp H, Baumgartner R (Eds.) Photodynamic therapy with ALA: a clinical handbook, Cambridge: Royal Society of Chemistry, 249-259.
Morley N, Rapp A, Dittmar H, Salter L, Gould D, Greulich KO, Curnow A (2006). UVA-induced apoptosis studied by the new apo/necro-Comet-assay which distinguishes viable, apoptotic and necrotic cells. Mutagenesis, 21(2), 105-114. Abstract.  Author URL.

2005

Pye AJ, Campbell SM, Horton SJ, Salter L, Curnow A (2005). An in vitro investigation of the enhancement of 5-aminolaevulinic acid-induced photodynamic therapy for the treatment of nodular basal cell carcinoma using the hydroxypyridinone iron chelator CP94.  Author URL.
Curnow A, Campbell S, Leman J, Morton C, Salter L (2005). Enhancement of dermatological ALA-PDT with an iron chelating agent (CP94).
Campbell S, Gould D, Salter L, Curnow A (2005). Penile intraepidermal neoplasia treated with MAL-PDT.  Author URL.
Morley N, Clifford T, Salter L, Campbell S, Gould D, Curnow A (2005). The green tea polyphenol (-)-epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage. Photodermatol Photoimmunol Photomed, 21(1), 15-22. Abstract.  Author URL.

2004

Campbell SM, Gould DJ, Salter L, Clifford T, Curnow A (2004). Photodynamic therapy using meta-tetrahydroxyphenylchlorin (Foscan) for the treatment of vulval intraepithelial neoplasia. Br J Dermatol, 151(5), 1076-1080. Abstract.  Author URL.
Morley N, Clifford T, Salter L, Campbell S, Gould D, Pye A, Curnow A (2004). The green tea polyphenol (-)-epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage.  Author URL.
Salter L, Clifford T, Morley N, Gould D, Campbell S, Curnow A (2004). The use of comet assay data with a simple reaction mechanism to evaluate the relative effectiveness of free radical scavenging by quercetin, epigallocatechin gallate and N-acetylcysteine in UV-irradiated MRC5 lung fibroblasts. J Photochem Photobiol B, 75(1-2), 57-61. Abstract.  Author URL.
Morton CA, Campbell S, Gould D, Curnow A (2004). Topical photodynamic therapy with the iron chelator, CP94, for nodular basal cell carcinoma.  Author URL.

2003

Campbell S, Leman J, Curnow A, Morton C, Salter L, Gould D (2003). Enhancing dermatological 5-aminolaevulinic acid-photodynamic therapy with a novel iron chelator.  Author URL.
Morley N, Curnow A, Salter L, Campbell S, Gould D (2003). N-acetyl-L-cysteine prevents DNA damage induced by UVA, UVB and visible radiation in human fibroblasts. J Photochem Photobiol B, 72(1-3), 55-60. Abstract.  Author URL.
Gould D, Curnow A, Morley N, Salter L (2003). Synergy between pollutants and ultraviolet radiation: a comet assay investigation.  Author URL.
Morley RN, Dittmar H, Curnow A, Salter L, Gould D, Greulich KO (2003). Two waves of apoptosis occur after UV-A exposure as detected with repeated scanning comet-assay.  Author URL.

2002

Stentiford FWM, Morley N, Curnow A (2002). Automatic identification of regions of interest with application to the quantification of DNA damage in cells.  Author URL.
Kömerik N, Curnow A, MacRobert AJ, Hopper C, Speight PM, Wilson M (2002). Fluorescence biodistribution and photosensitising activity of toluidine blue o on rat buccal mucosa. Lasers Med Sci, 17(2), 86-92. Abstract.  Author URL.
Tsutsui H, MacRobert AJ, Curnow A, Rogowska A, Buonaccorsi G, Kato H, Bown SG (2002). Optimisation of illumination for photodynamic therapy with mTHPC on normal colon and a transplantable tumour in rats. Lasers Med Sci, 17(2), 101-109. Abstract.  Author URL.
Curnow A, Salter L, Morley N, Campbell S, Gould D (2002). Paracetamol can exacerbate irradiation-induced DNA damage. Br J Clin Pharmacol, 53(3), 338-340. Author URL.
Curnow A, Bown SG (2002). The role of reperfusion injury in photodynamic therapy with 5-aminolaevulinic acid--a study on normal rat colon. Br J Cancer, 86(6), 989-992. Abstract.  Author URL.  Full text.
ACurnow, Bown S (2002). The role of reperfusion injury in photodynamic therapy with aminolaevulinic acid - a study on normal rat colon. British Journal of Cancer, 86(6), 989-992.

2001

Curnow A, Salter L, Morley N, Gould D (2001). A preliminary investigation of the effects of arsenate on irradiation-induced DNA damage in cultured human lung fibroblasts. J Toxicol Environ Health A, 63(8), 605-616. Abstract.  Author URL.
Curnow A, Parsons B, Salter L, Morley N, Gould D (2001). An investigation of the genotoxic effects of airborne particulate matter using single-cell gel electrophoresis.

2000

Curnow A, Gould D, Salter L (2000). A new method for the cultivation of human naevus melanocytes.
Connell RJ, Curnow A, Cutner A, Brown S (2000). Endometrial ablation in the rabbit uterus by photodynamic therapy (PDT) using 5-aminolaevulinic acid with the iron chelator CP94. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 107(6), 828-828. Author URL.
Curnow A, Haller JC, Bown SG (2000). Oxygen monitoring during 5-aminolaevulinic acid induced photodynamic therapy in normal rat colon. Comparison of continuous and fractionated light regimes. J Photochem Photobiol B, 58(2-3), 149-155. Abstract.  Author URL.  Full text.

1999

Curnow A, McIlroy BW, Postle-Hacon MJ, MacRobert AJ, Bown SG (1999). Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol, 69(1), 71-76. Abstract.  Author URL.

1998

Curnow A, McIlroy B, Postle-Hacon M, Porter J, MacRobert A, Bown S (1998). Enhancement of 5-aminolaevulinic acid induced photodynamic therapy using iron chelating agents. British Journal of Cancer, 78, 1278-1282.
Curnow A, Postle-Hacon MJ, MacRobert AJ, Brown SG (1998). Enhancement of 5-aminolaevulinic acid induced photodynamic therapy using light dose fractionation and iron chelating agents.  Author URL.
Curnow A, McIlroy BW, Postle-Hacon MJ, Porter JB, MacRobert AJ, Bown SG (1998). Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents. Br J Cancer, 78(10), 1278-1282. Abstract.  Author URL.  Full text.
McIlroy BW, Curnow A, Buonaccorsi G, Scott MA, Bown SG, MacRobert AJ (1998). Spatial measurement of oxygen levels during photodynamic therapy using time-resolved optical spectroscopy. J Photochem Photobiol B, 43(1), 47-55. Abstract.  Author URL.
Komerik N, Speight P, Curnow A, Postle-Hacon M, Wilson M, Hopper C (1998). The effect of photodynamic therapy on rat buccal mucosa. JOURNAL OF DENTAL RESEARCH, 77, 754-754. Author URL.

1994

Twelves CJ, Dobbs NA, Curnow A, Coleman RE, Stewart AL, Tyrrell CJ, Canney P, Rubens RD (1994). A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer, 70(5), 990-993. Abstract.  Author URL.  Full text.

Awards

  • Above & Beyond Awards
  • Merit Awards
  • Teaching Award Nominations
  • British Medical Laser Association Conference Presentation Award (Liverpool, 1999)
  • International Photodynamic Association Scientific Communication Prize (Nantes, 1998)
  • International Photodynamic Association Student Investigator Award (Melbourne, 1996)
  • Wellcome Foundation Biochemistry Prize (Guildford, 1994)

Committee/panel activities

 Secretary General (2009-13) and Director (2005-16) of the International Photodynamic Association.


Editorial responsibilities

Editor of the Journal of Photochemistry & Photobiology B: Biology (2001-10).

As an experienced and long-serving member of the core academic faculty of the Medical School (2003 to date), Alison has been extensively involved in the strategic leadership and management of the development, delivery and assessment of many of the School’s undergraduate and postgraduate educational programmes.  This currently includes being Deputy Director of Undergraduate Medicine (BMBS) as well as the Programme Lead for our MSc in Environment & Human Health.

Back | Edit Profile